Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

Rhea-AI Summary

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will report third quarter financial results on Nov. 13, 2023. The company is developing a novel therapeutic for Alzheimer's disease. A conference call and live webcast will be held at 8:00 a.m. ET for a business and financial update. Registration is required to participate.

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report third quarter financial results on Monday, Nov. 13, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance. 

The webcast audio will be available via this link. 

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive topline results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Investors:

Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com 

FAQ

When will Acumen Pharmaceuticals report its third quarter financial results?

Acumen Pharmaceuticals will report its third quarter financial results on Nov. 13, 2023.

What is Acumen Pharmaceuticals developing?

Acumen Pharmaceuticals is developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease.

What will be discussed during the conference call and webcast?

The conference call and webcast will provide a business and financial update.

How can I participate in the live conference call?

To participate in the live conference call, you need to register using the provided link. After registration, you will receive the dial-in numbers and PIN.

Where can I find the archived version of the webcast?

The archived version of the webcast will be available for at least 30 days in the Investors section of Acumen Pharmaceuticals' website at www.acumenpharm.com.